Skip to main content

Table 3 Dengue antibody response post-dose 3 by baseline FV status

From: Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults

  Group 1 (N = 117) Group 2 (N = 119)
FV Seropositivea
(N = 63)
FV Seronegativeb
(N = 54)
FV Seropositivea
(N = 65)
FV Seronegativeb
(N = 54)
n GMT (95% CI) Seropositive % n GMT (95% CI) Seropositive % n GMT (95% CI) Seropositive % n GMT (95% CI) Seropositive %
Serotype 1
 Baseline 63 5.73 (4.72–6.94) 3.2 (0.4–11.0) 54 5.00 (NC) 0.0 (0.0–6.6) 65 5.23 (4.96–5.53) 4.6 (1.0–12.9) 54 5.00 (NC) 0.0 (0.0–6.6)
 28 days post-dose 3 51 15.6 (10.6–23.0) 54.9 (40.3–68.9) 42 13.9 (9.49–20.4) 50.0 (34.2–65.8) 59 17.2 (12.7–23.3) 61.0 (47.4–73.5) 49 14.4 (10.1–20.7) 51.0 (36.3–65.6)
 6 months post-dose 3 49 14.8 (10.0–21.7) 53.1 (38.3–67.5) 39 11.7 (8.04–17.1) 41.0 (25.6–57.9) 58 10.3 (7.85–13.4) 36.2 (24.0–49.9) 46 7.63 (6.16–9.46) 28.3 (16.0–43.5)
 12 months post-dose 3   NA   NA 55 9.35 (7.50–11.7) 40.0 (27.0–54.1) 44 7.45 (5.87–9.47) 25.0 (13.2–40.3)
Serotype 2
 Baseline 63 5.35 (4.67–6.13) 1.6 (0.0–8.5) 54 5.00 (NC) 0.0 (0.0–6.6) 65 5.42 (4.93–5.96) 4.6 (1.0–12.9) 54 5.00 (NC) 0.0 (0.0–6.6)
 28 days post-dose 3 52 60.0 (39.4–91.4) 84.6 (71.9–93.1) 42 42.1 (27.9–63.4) 83.3 (68.6–93.0) 59 68.1 (48.9–94.7) 94.9 (85.9–98.9) 49 51.4 (32.8–80.6) 79.6 (65.7–89.8)
 6 months post-dose 3 49 52.5 (32.1–85.8) 79.6 (65.7–89.8) 39 38.1 (21.7–67.0) 69.2 (52.4–83.0) 58 53.0 (37.4–75.2) 91.4 (81.0–97.1) 46 26.0 (17.2–39.3) 67.4 (52.0–80.5)
 12 months post-dose 3   NA   NA 56 32.7 (22.6–47.4) 82.1 (69.6–91.1) 44 22.9 (15.5–33.7) 68.2 (52.4–81.4)
Serotype 3
 Baseline 63 5.61 (4.89–6.45) 4.8 (1.0–13.3) 54 5.00 (NC) 0.0 (0.0–6.6) 65 5.53 (5.06–6.05) 7.7 (2.5–17.0) 54 5.00 (NC) 0.0 (0.0–6.6)
 28 days post-dose 3 52 44.8 (31.3–64.3) 84.6 (71.9–93.1) 42 46.9 (30.9–71.2) 85.7 (71.5–94.6) 59 71.2 (53.4–94.8) 94.9 (85.9–98.9) 48 47.3 (32.5–69.0) 85.4 (72.2–93.9)
 6 months post-dose 3 49 33.0 (23.4–46.5) 85.7 (72.8–94.1) 39 27.1 (16.6–44.3) 71.8 (55.1–85.0) 58 48.5 (36.0–65.3) 87.9 (76.7–95.0) 46 22.5 (16.3–31.0) 71.7 (56.5–84.0)
 12 months post-dose 3   NA   NA 56 24.1 (17.6–33.0) 73.2 (59.7–84.2) 44 15.4 (11.1–21.2) 61.4 (45.5–75.6)
Serotype 4
 Baseline 63 6.55 (5.32–8.07) 12.7 (5.6–23.5) 54 5.00 (NC) 0.0 (0.0–6.6) 65 5.20 (4.81–5.63) 1.5 (0.0–8.3) 54 5.00 (NC) 0.0 (0.0–6.6)
 28 days post-dose 3 52 51.7 (35.1–76.2) 82.7 (69.7–91.8) 42 91.8 (63.3–133) 95.2 (83.8–99.4) 59 78.5 (54.3–114) 88.1 (77.1–95.1) 48 89.2 (53.3–149) 83.3 (69.8–92.5)
 6 months post-dose 3 49 60.0 (38.4–93.8) 81.6 (68.0–91.2) 39 98.7 (64.8–150) 92.3 (79.1–98.4) 58 39.8 (26.9–59.0) 70.7 (57.3–81.9) 46 44.3 (28.3–69.5) 78.3 (63.6–89.1)
 12 months post-dose 3   NA   NA 56 46.9 (32.2–68.4) 80.4 (67.6–89.8) 44 48.7 (30.5–77.5) 81.8 (67.3–91.8)
  1. GMT geometric mean titre, n number of participants with available data for endpoint, NA not applicable, NC not calculated
  2. aFV seropositive participants at baseline defined as: participants with ≥10 1/dil for at least 1 dengue serotype (sera tested by PRNT) or for YF virus (sera with PRNT80)
  3. bFV seronegative participants are defined as those participants with < 10 1/dil for all dengue serotypes and for YF virus (using sera with PRNT80)